Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Victoria Atkinson et al.|New England Journal of Medicine|2017Cited by 1.5k
Design and manufacturing of biomimetic scaffolds for bone repair inspired by bone trabeculaeDeyin Kong, Yiling Li, Qing Wang et al.|Computers in Biology and Medicine|2023Cited by 23
Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.James Larkin, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 11
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.Dirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 10
Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant MelanomaGeorgina V. Long, John M. Kirkwood, Axel Hauschild et al.|SKIN The Journal of Cutaneous Medicine|2018Cited by 1